Guzzi Leda, Sambade Juan Manuel, Christin Martin Diego, Rodriguez Cairoli Federico, Rodriguez Alejandra, Vicario Silvia, Hinojosa Del Carpio Miriam, Molinos Juan, Dimitroff Pablo
Clínica Olivos, Swiss Medical Group, Vicente López, Argentina; Sociedad Argentina de Infectología, Argentina.
Clínica Olivos, Swiss Medical Group, Vicente López, Argentina.
Rev Argent Microbiol. 2024 Jan-Mar;56(1):62-68. doi: 10.1016/j.ram.2023.06.003. Epub 2023 Jul 5.
Interaction between severe acute respiratory coronavirus 2 (SARS-CoV-2) and IIEB remains under investigation. Objective: to compare IIEB incidence before and during COVID-19 pandemic, and assess incidence of coinfection with COVID-19 and case fatality. A cross-sectional study was performed on data from a centralized microbiology laboratory serving a network of healthcare centers comprising 713 pediatric and adult inpatient beds, expanded by 20% during the pandemic. Three periods were evaluated: (1) pre-pandemic: March 1, 2019-February 29, 2020; (2) pandemic year 1: March 1, 2020-February 28, 2021; (3) pandemic year 2: March 1, 2021-July 31, 2021. Descriptive statistical analysis was performed. 56 502 samples (96% blood cultures) from 27224 patients were analyzed. Of these, 54 samples (from 54 patients) were positive for encapsulated bacteria. IIEB incidence was: 167.4, 32.6, and 50.4 per 100000 samples for periods 1, 2, and 3, respectively. Twelve IIEB episodes occurred during the pandemic period: 10 Streptococcus pneumoniae, and 2 Haemophilus influenzae, of which 7 were SARS-CoV-2/S. pneumoniae coinfections, with an incidence of 5.68 per 10000 COVID-19-related hospitalizations (0.056%). IIEB case fatality was 31%, 29%, and 60% for each period, respectively, 3/7 patients with coinfection died (43%). Case fatality for invasive pneumococcal disease (IPD) in patients without COVID-19, was 32.5%. Significant reduction in IIEB incidence was observed during the pandemic, coinciding with implementation of containment measures. The incidence of SARS-CoV-2/S. pneumoniae coinfection was low, with higher case fatality than IPD patients without COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与侵袭性感染性心内膜炎（IIEB）之间的相互作用仍在研究中。目的：比较COVID-19大流行之前和期间IIEB的发病率，并评估COVID-19合并感染的发病率和病死率。对一家为包括713张儿科和成人住院病床的医疗中心网络服务的中央微生物实验室的数据进行了横断面研究，在大流行期间床位增加了20%。评估了三个时期：（1）大流行前：2019年3月1日至2020年2月29日；（2）大流行第1年：2020年3月1日至2021年2月28日；（3）大流行第2年：2021年3月1日至2021年7月31日。进行了描述性统计分析。分析了来自27224名患者的56502份样本（96%为血培养样本）。其中，54份样本（来自54名患者）的包膜细菌呈阳性。IIEB发病率分别为：第1、2和3时期每100000份样本中为167.4、32.6和50.4例。大流行期间发生了12例IIEB发作：10例肺炎链球菌，2例流感嗜血杆菌，其中7例为SARS-CoV-2/肺炎链球菌合并感染，每10000例与COVID-19相关的住院患者中的发病率为5.68例（0.056%）。每个时期IIEB的病死率分别为31%、29%和60%，7例合并感染患者中有3例死亡（43%）。无COVID-19患者的侵袭性肺炎球菌病（IPD）病死率为32.5%。在大流行期间观察到IIEB发病率显著降低，这与防控措施的实施相吻合。SARS-CoV-2/肺炎链球菌合并感染的发病率较低，病死率高于无COVID-19的IPD患者。
